Bruce H. Gray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bruce H. Gray has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Andrew B. Dicks
University of South Carolina School of Medicine-Greenville, Greenville, South Carolina
3 shared publications- Andrew B. Dicks
Prisma Health, Greenville, SC, USA
2 shared publications Christopher G. Carsten
University of Cincinnati, School of Medicine, Cincinnati, OH
2 shared publicationsChristopher J. White
John Ochsner Heart & Vascular institute, Ochsner Medical Center New Orleans Louisiana
2 shared publicationsElias Wheibe
University of Cincinnati, School of Medicine, Cincinnati, OH
2 shared publications- Heather L. Gornik
Harrington Heart & Vascular Institute, University Hospitals, Cleveland, OH, USA
2 shared publications
Latest Publications
- 26 May 2025
- Published by Elsevier in Advances in Surgery
- Vol. 59 (1) , 77-92
Clinical Decision-Making for Patients with Chronic Limb-Threatening Ischemia
- 26 May 2025
- Published by Elsevier in Advances in Surgery
- Vol. 59 (1) , 77-92
Clinical Decision-Making for Patients with Chronic Limb-Threatening Ischemia
- 16 April 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (16) , 1241-1253
Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization
BACKGROUND: In the BEST-CLI trial (Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb-Threatening Ischemia), a prespecified secondary objective was to assess the effects of revascularization strategy on health-related quality of life (HRQoL). METHODS: Patients with chronic limb-threatening ischemia were randomized to surgical bypass (Bypass) or endovascular intervention (Endo) in 2 parallel trials. Cohort 1 included patients with single-segment great saphenous vein; cohort 2 included those lacking suitable single-segment great saphenous vein. HRQoL was assessed over the trial duration using Vascular Quality-of-Life (VascuQoL), European Quality-of-Life-5D (EQ-5D), the Short Form-12 (SF-12) Physical Component Summary (SF-12 PCS), SF-12 Mental Component Summary (SF-12 MCS), Utility Index Score (SF-6D R2), and numeric rating scales of pain. HRQoL was summarized by cohort and compared within and between groups using mixed-model linear regression. RESULTS: A total of 1193 and 335 patients in cohorts 1 and 2 with a mean follow-up of 2.9 and 2.0 years, respectively, were analyzed. In cohort 1, HRQoL significantly improved from baseline to follow-up for both groups across all measures. For example, mean (SD) VascuQoL scores were 3.0 (1.3) and 3.0 (1.2) for Bypass and Endo at baseline and 4.7 (1.4) and 4.8 (1.5) over follow-up. There were significant group differences favoring Endo when assessed with VascuQoL (difference, –0.14 [95% CI, –0.25 to –0.02]; P =0.02), SF-12 MCS (difference, –1.03 [95% CI, –1.89 to –0.18]; P =0.02), SF-6D R2 (difference, –0.01 [95% CI, –0.02 to –0.001]; P =0.03), numeric rating scale pain at present (difference, 0.26 [95% CI, 0.03 to 0.49]; P =0.03), usual level during previous week (difference, 0.26 [95% CI, 0.04 to 0.48]; P =0.02), and worst level during previous week (difference, 0.29 [95% CI, 0.02 to 0.56]; P =0.04). There was no difference between treatment arms on the basis of EQ-5D (difference, –0.01 [95% CI, –0.03 to 0.004]; P =0.12) or SF-12 PCS (difference, –0.41 [95% CI, –1.2 to 0.37]; P =0.31). In cohort 2, HRQoL also significantly improved from baseline to the end of follow-up for both groups based on all measures, but there were no differences between Bypass and Endo on any measure. CONCLUSIONS: Among patients with chronic limb-threatening ischemia deemed eligible for either Bypass or Endo, revascularization resulted in significant and clinically meaningful improvements in HRQoL. In patients with an available single-segment great saphenous vein for bypass, but not among those without one, Endo was statistically superior on some HRQoL measures; however, these differences were below the threshold of clinically meaningful difference.
- 16 April 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (16) , 1241-1253
Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization
BACKGROUND: In the BEST-CLI trial (Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb-Threatening Ischemia), a prespecified secondary objective was to assess the effects of revascularization strategy on health-related quality of life (HRQoL). METHODS: Patients with chronic limb-threatening ischemia were randomized to surgical bypass (Bypass) or endovascular intervention (Endo) in 2 parallel trials. Cohort 1 included patients with single-segment great saphenous vein; cohort 2 included those lacking suitable single-segment great saphenous vein. HRQoL was assessed over the trial duration using Vascular Quality-of-Life (VascuQoL), European Quality-of-Life-5D (EQ-5D), the Short Form-12 (SF-12) Physical Component Summary (SF-12 PCS), SF-12 Mental Component Summary (SF-12 MCS), Utility Index Score (SF-6D R2), and numeric rating scales of pain. HRQoL was summarized by cohort and compared within and between groups using mixed-model linear regression. RESULTS: A total of 1193 and 335 patients in cohorts 1 and 2 with a mean follow-up of 2.9 and 2.0 years, respectively, were analyzed. In cohort 1, HRQoL significantly improved from baseline to follow-up for both groups across all measures. For example, mean (SD) VascuQoL scores were 3.0 (1.3) and 3.0 (1.2) for Bypass and Endo at baseline and 4.7 (1.4) and 4.8 (1.5) over follow-up. There were significant group differences favoring Endo when assessed with VascuQoL (difference, –0.14 [95% CI, –0.25 to –0.02]; P =0.02), SF-12 MCS (difference, –1.03 [95% CI, –1.89 to –0.18]; P =0.02), SF-6D R2 (difference, –0.01 [95% CI, –0.02 to –0.001]; P =0.03), numeric rating scale pain at present (difference, 0.26 [95% CI, 0.03 to 0.49]; P =0.03), usual level during previous week (difference, 0.26 [95% CI, 0.04 to 0.48]; P =0.02), and worst level during previous week (difference, 0.29 [95% CI, 0.02 to 0.56]; P =0.04). There was no difference between treatment arms on the basis of EQ-5D (difference, –0.01 [95% CI, –0.03 to 0.004]; P =0.12) or SF-12 PCS (difference, –0.41 [95% CI, –1.2 to 0.37]; P =0.31). In cohort 2, HRQoL also significantly improved from baseline to the end of follow-up for both groups based on all measures, but there were no differences between Bypass and Endo on any measure. CONCLUSIONS: Among patients with chronic limb-threatening ischemia deemed eligible for either Bypass or Endo, revascularization resulted in significant and clinically meaningful improvements in HRQoL. In patients with an available single-segment great saphenous vein for bypass, but not among those without one, Endo was statistically superior on some HRQoL measures; however, these differences were below the threshold of clinically meaningful difference.
- 15 March 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (2) , 109-111
The time is now for vascular medicine
- 15 March 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (2) , 109-111
The time is now for vascular medicine
- Top Cited PapersOpen Access
- 9 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 362
A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism
Venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), is a significant cause of morbidity and mortality worldwide. There are many factors, both acquired and inherited, known to increase the risk of VTE. Most of these result in increased risk via several common mechanisms including circulatory stasis, endothelial damage, or increased hypercoagulability. Overall, a risk factor can be identified in the majority of patients with VTE; however, not all risk factors carry the same predictive value. It is important for clinicians to understand the potency of each individual risk factor when managing patients who have a VTE or are at risk of developing VTE. With this, many providers consider performing a thrombophilia evaluation to further define a patient’s risk. However, guidance on who to test and when to test is controversial and not always clear. This comprehensive review attempts to address these aspects/concerns by providing an overview of the multifaceted risk factors associated with VTE as well as examining the role of performing a thrombophilia evaluation, including the indications and timing of performing such an evaluation.
- 9 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (2) , 362
Top Cited PapersOpen AccessA Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism
Venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), is a significant cause of morbidity and mortality worldwide. There are many factors, both acquired and inherited, known to increase the risk of VTE. Most of these result in increased risk via several common mechanisms including circulatory stasis, endothelial damage, or increased hypercoagulability. Overall, a risk factor can be identified in the majority of patients with VTE; however, not all risk factors carry the same predictive value. It is important for clinicians to understand the potency of each individual risk factor when managing patients who have a VTE or are at risk of developing VTE. With this, many providers consider performing a thrombophilia evaluation to further define a patient’s risk. However, guidance on who to test and when to test is controversial and not always clear. This comprehensive review attempts to address these aspects/concerns by providing an overview of the multifaceted risk factors associated with VTE as well as examining the role of performing a thrombophilia evaluation, including the indications and timing of performing such an evaluation.
- 19 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 6-10
Reclaiming the Bedside of the Vascular Patient
- 19 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 6-10
Reclaiming the Bedside of the Vascular Patient
- 16 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 11-14
Refining Vascular Care Through Science Without Losing the Art
- 16 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 11-14
Refining Vascular Care Through Science Without Losing the Art
- 16 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 1-5
The Importance of Team Alignment and Retention in Vascular Center Development: A Clinician’s Perspective
- 16 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 1-5
The Importance of Team Alignment and Retention in Vascular Center Development: A Clinician’s Perspective
- 16 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 219-220
Introduction to Virtual Supplement to Annals of Vascular Surgery
- 16 December 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 101, 219-220
Introduction to Virtual Supplement to Annals of Vascular Surgery
- 1 November 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 99, 434-441
Outcomes of Endovascular Treatment for Critical Limb Threatening Ischemia
- 1 November 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 99, 434-441
Outcomes of Endovascular Treatment for Critical Limb Threatening Ischemia